Neoplasms by Histologic Type  >>  Genasense (oblimersen)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Genasense (oblimersen) / Genta
NCT00024440: Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Completed
3
US
filgrastim, oblimersen sodium, cyclophosphamide, fludarabine phosphate
Genta Incorporated
Leukemia
 
02/07
NCT00085124: Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Completed
3
500
US
oblimersen sodium, augmerosen, G3139, G3139 bcl-2 antisense oligodeoxynucleotide, Genasense, cytarabine, ARA-C, arabinofuranosylcytosine, arabinosylcytosine, Cytosar-U, cytosine arabinoside, daunorubicin hydrochloride, Cerubidin, Cerubidine, daunomycin hydrochloride, daunorubicin, RP-13057, laboratory biomarker analysis
National Cancer Institute (NCI)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
06/07
 
NCT00017602: Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed
3
US
oblimersen sodium, dexamethasone
Genta Incorporated
Multiple Myeloma and Plasma Cell Neoplasm
 
04/09

Download Options